The dual inhibition of CDK4/6 with abemaciclib and Bcl-2 with venetoclax has been shown to induce synergistic anti-MCL activity in a variety of in vitro and in vivo preclinical relapsed/refractory MCL models (Che et al., 2023). This evidence concerns the gene BCL2 and mantle cell lymphoma.